New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For TEVA;NPSP;CELG;AZN;ACOR;PFE;ALKS;PRXL;MEDI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 23, 2015
19:15 EDTNPSPNPS Pharmaceuticals announces FDA approval of Natpara
Subscribe for More Information
16:08 EDTTEVA, PFETeva volatility elevated, Pfizer approached late last year, Bloomberg says
Teva (TEVA) overall option implied volatility of 25 compares to its 26-week average of 23 according to Track Data, suggesting large price movement into Pfizer (PFE) approach late last year, Bloomberg says.
16:04 EDTTEVA, PFETeva rebuffed Pfizer approach late last year, Bloomberg says
Subscribe for More Information
07:21 EDTCELGCelgene receives positive CHMP opinion for ABRAXANE
Subscribe for More Information
January 22, 2015
11:23 EDTPFEPfizer says CHMP adopted positive opinion on Prevenar 13 expansion
Subscribe for More Information
January 21, 2015
12:30 EDTPFE, AZNGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
10:16 EDTAZNLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
08:38 EDTTEVAMomenta announces Supreme Court decision to remand generic Copaxone back to CAFC
Subscribe for More Information
08:36 EDTCELGCelgene price target raised to $139 from $115 at RW Baird
Baird raised its price target on Celgene to $139 from $115 following last week's guidance from the company. Baird reiterated its Outperform rating on Celgene shares.
January 20, 2015
14:37 EDTTEVATeva generic competition to Copaxone pushed out by ruling, says BMO Capital
Subscribe for More Information
12:56 EDTTEVAMylan says continues to believe '808 patent is 'invalid'
Subscribe for More Information
11:29 EDTTEVATeva says Supreme Court reverses circuit court judgment on Copaxone 20 mg/mL
Teva Pharmaceutical announced the U.S. Supreme Court’s decision in Teva Pharmaceuticals USA, Inc. et al. Petitioners v. Sandoz Inc. et al. that reversed the Federal Circuit Court’s judgment of invalidity of Teva’s ‘808 patent for COPAXONE 20 mg/mL. The Supreme Court remanded the case to the Federal Circuit for further review in light of the applicable standard the Supreme Court laid out for appellate review of claim construction. A ruling last year by the U.S. Court of Appeals for the Federal Circuit upheld four Teva patents that expired in May 2014, while invalidating the ‘808 patent that is set to expire on September 1, 2015. “We are encouraged by the U.S. Supreme Court’s Decision and look forward to the Federal Circuit’s review. We will continue to explore all available avenues to protect our intellectual property for COPAXONE 20mg/mL,” said Erez Vigodman, President and CEO of Teva. “There is currently no FDA-approved follow-on version of Teva’s COPAXONE. We are encouraged by the FDA’s willingness to date to have dialogue regarding the complexities of COPAXONE 20 mg/mL and the potential limitations and other unknowns of purported follow-on versions,” added Rob Koremans, MD, President and CEO of Global Specialty Medicines at Teva.
10:45 EDTTEVATeva spikes, retraces, after win in Copaxone patent case
Subscribe for More Information
10:40 EDTTEVAMomenta Pharma sinks after Supreme Court rules on Copaxone
Subscribe for More Information
10:35 EDTTEVATeva rises after patent ruling upheld by Supreme Court
The Supreme Court upheld a lower court ruling related to generic versions of Teva's Copaxone drug. In the ruling, the court wrote that "When reviewing a district court’s resolution of subsidiary factual matters made in the course of its construction of a patent claim, the Federal Circuit must apply a “clear error,” not a de novo, standard of review." Teva shares are up 1.5% to $58.58 in early trading after the ruling. Reference Link
10:20 EDTNPSPOptions with decreasing implied volatility
Options with decreasing implied volatility: RPRX TLM BBY GME CBST NPSP
08:49 EDTPRXLPAREXEL downgraded to Neutral from Buy at SunTrust
SunTrust downgraded PAREXEL based on full valuation. Price target remains $65.
06:09 EDTPRXLPAREXEL downgraded to Neutral from Buy at SunTrust
Subscribe for More Information
January 16, 2015
16:36 EDTNPSPMarket finishes week lower on continued oil, global growth worries
Subscribe for More Information
09:11 EDTCELGCelgene says oral Otezla approved by European Commission in 2 indications
Celgene International, a wholly-owned subsidiary of Celgene Corporation, announced that the European Commission has granted marketing authorisation for OTEZLA, the company’s oral selective inhibitor of phosphodiesterase 4, in two therapeutic indications: For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light. Alone or in combination with Disease Modifying Antirheumatic Drugs, for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. The marketing authorization is based on efficacy and safety data from two Phase III programs, ESTEEM AND PALACE, which demonstrate a maintained clinical response among patients with psoriasis and psoriatic arthritis treated with OTEZLA through 52 weeks, across multiple endpoints. The EC decision follows the positive opinion issued by the Committee for Medicinal Products for Human Use in November 2014.12 OTEZLA will be launched in the European Union in the coming months in accordance with local requirements.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use